| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
| Citibank | ||||||||
| Legacy Pharma Inc |
In the Phase III Krascendo 1 study, divarasib monotherapy reduced the risk of disease progression or death by 42% and the risk of death by 44% compared with first-generation KRAS G12C inhibitors. Median overall survival was approximately 18 months with divarasib, versus 12 months with sotorasib or adagrasib. No new safety signals were observed, and the most common treatment-related adverse events were mainly low grade and manageable.
Genentech reported interim Phase III data showing that the antisense oligonucleotide Sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks. The drug, the first ASO evaluated in IgA nephropathy, inhibits complement factor B production and may slow disease progression by reducing kidney inflammation. It is designed as a once‑monthly subcutaneous injection for patient convenience.
Genentech presented new pivotal trial data at MSToronto2026, showing Fenebrutinib’s therapeutic effect on chronic active lesions and a 55% reduction in annualized relapse rate versus an active comparator. Ocrevus OPERETTA 2 Phase III data demonstrated that 90% of children aged 10–17 remained relapse‑free over two years, underscoring consistent MS control across ages. Enspryng METEOROID Phase III data were also highlighted in the presentation.
Genentech will present late-stage lung and breast cancer data at ESMO 2026. Phase III results showed divarasib was superior to first-generation KRAS G12C inhibitors in previously treated advanced KRAS G12C-mutated non-small cell lung cancer. Patient-reported outcomes from the Phase III lidERA study showed improved efficacy with giredestrant over standard endocrine therapy without compromising tolerability or health-related quality of life in early-stage breast cancer.
The FDA has approved Genentech’s Enspryng (satralizumab‑mwge), a first‑in‑class IL‑6R inhibitor, as the first and only at‑home subcutaneous treatment for thyroid eye disease (TED). Phase III SatraGO‑1 and SatraGO‑2 studies showed significant reductions in proptosis and diplopia with a favorable safety profile, regardless of disease activity or duration. Enspryng offers patients a flexible, quarterly at‑home maintenance option.
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with uveitic macular edema (UME) at 52 weeks.
The FDA approved Genentech’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of a certain type of stage III colon cancer. The approval was based on the Phase III ATOMIC study, published in The New England Journal of Medicine, which found the combination reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone.
An estimated 225,000 women in the United States will be diagnosed with hormone receptor-positive, HER2-negative breast cancer in 2026. It is the most common type, accounting for about 70% of all cases.
Genentech announced new real-world data for Vabysmo at EURETINA, showing its effectiveness and safety in treating major retinal conditions such as wet AMD, DME, and RVO. The results demonstrate robust effectiveness and durability, with no new safety concerns.
In patients with ER-positive advanced breast cancer, the combination of giredestrant and everolimus significantly reduced the risk of disease progression or death compared with standard therapy. Results from the phase III evERA trial were published in The New England Journal of Medicine.